Neurosonic
Entrepreneur First '24London, GB · Founded 2024 · 6 known investors
NeuroSonic develops a handheld, non-invasive device that assesses stroke risk by analyzing carotid artery blood flow, enabling clinicians to determine which patients require further vascular imaging. The device is designed for use in clinical settings to accelerate stroke-risk assessment and improve prevention.
Also known as NeuroSonic
Founders & leadership
Neurosonic was founded in 2024 by Mike Ryan and Matthew Campbell.
Investors · 6
Company profile
researched Aug 2026NeuroSonic develops a handheld, non-invasive device intended for use by licensed healthcare professionals to assess blood flow in the carotid arteries as an indicator of stroke risk. In the described workflow, a clinician or trained staff member places the device on each side of the patient's neck, the device analyses blood flow, and results are presented in a companion app. The app displays a carotid artery assessment, including graded stenosis findings for the left and right carotid arteries (for example, mild 0-49% narrowing or moderate 50-69% narrowing), along with raw waveform views.
The company positions the device as a triage aid rather than a replacement for imaging: it is intended to help clinicians decide whether a patient requires further vascular imaging, with conventional ultrasound or other imaging remaining the next step when risk is indicated. Marketing materials emphasise ease of use with minimal training, results that are intended to be consistent regardless of operator skill, near-instant output, and integration with existing hospital systems. The website frames the problem using US stroke statistics (approximately 800,000 strokes annually, 1 in 4 lifetime risk, 80% of strokes described as preventable).
The product is described as currently undergoing clinical validation and regulatory review, with availability dependent on local regulatory status. The company states that patient data is handled under security and privacy protocols, with market-specific compliance standards to be detailed as approvals are completed.
Founding story
Not described in the available sources beyond the identification of Mike Ryan and Matthew Campbell as co-founders [0][1].
Business model
Not specified in the sources. The device is positioned for use by clinicians in hospital and clinical settings, paired with an app and integration into existing hospital systems, implying a business-to-provider model, though no pricing or contracting details are disclosed [0][1].
Not disclosed in the available sources.
Traction
The website lists a set of partners spanning venture and institutional backers and health systems: Emergent Ventures, Entrepreneurs First, Transpose Platform, Stanford Healthcare, MGB, Henry Ford Healthcare, Providence Medical System, University Clinical Center Gdansk, Vastrax, Detroit Venture Partners, Long Journey Ventures and Anorak Ventures. The nature and status of each relationship is not specified. The product is described as undergoing clinical validation and regulatory review; no revenue, deployment or user metrics are disclosed [0][1].
Latest developments
The company states the device is currently in clinical validation and regulatory review, with market availability contingent on approvals. The team page lists Mike Ryan (Co-founder & CEO), Matthew Campbell (Co-founder & CPO) and Alan Solinski (Founding Engineer); a careers link indicates active hiring. Startup Map London labels the company as Series A stage, though no round details are provided [0][1][4].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Early-stage medical device company positioned between no assessment and full vascular imaging, aiming to provide first-visit vascular insight without the cost, complexity or delay of traditional imaging. It is categorised on Startup Map London under Biotech, AI, Health Tech and Medical Device, and appears in the Entrepreneurs First portfolio [0][1][4][6].
Stated differentiators are operator-independent, near-instantaneous results requiring little training; point-of-care use during the first patient visit; and delivery of results through an app that integrates with hospital systems, in contrast to scheduled imaging pathways. The company explicitly states the device does not replace ultrasound or other imaging [0][1].
Technology
A handheld, non-invasive sensing device applied externally to both sides of the neck that analyses carotid artery blood flow and transmits results to a mobile application. The app reports graded carotid stenosis findings per side and provides access to raw carotid waveforms. The company states the design targets consistent output independent of operator skill and requires little to no training, with results available within moments and integration with hospital systems [0][1].
Go-to-market
Sold into clinical settings for use by clinicians and trained staff, with inbound contact via a website enquiry form; relationships with academic and health-system partners are listed but not detailed [0][1].
Licensed healthcare professionals and clinical care teams in everyday clinical settings; patients are directed to consult their clinician rather than to use the device directly [0][1].
Geography
Listed as a London startup and in the Entrepreneurs First portfolio; named partners include US health systems (Stanford Healthcare, MGB, Henry Ford Healthcare, Providence Medical System) and University Clinical Center Gdansk in Poland. Problem framing on the website references US stroke statistics [0][1][4][6].
History
Public sources give limited history. The company appears in the Entrepreneurs First portfolio and on Startup Map London as a London-based health-tech and medical-device startup, with a team of three named individuals on the website [0][1][4][6].
Risks & controversies
The product is not yet approved for clinical use and remains subject to clinical validation and regulatory review, with availability varying by jurisdiction. The device is explicitly not a replacement for ultrasound or other imaging, so adoption depends on its value as a triage step. Compliance standards for patient data handling are stated as still to be defined per market [0][1].
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Neurosonic for the same Google search keywords, organic and paid, via search-intersection analysis.
▸Research sources · 8
primary sources listed
- Neurosonicneuro-sonic.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Neurosonic do?
- UK developer of a handheld, non-invasive device that assesses carotid blood flow to flag stroke risk at the point of care.
- Who founded Neurosonic?
- Neurosonic was founded by Mike Ryan, Matthew Campbell in 2024.
- Who are Neurosonic's investors?
- Neurosonic's investors include Anorak Ventures, Detroit Venture Partners, EMERGENT VENTURES, Long Journey Ventures, Entrepreneur First, Transpose Platform Management.
- Where is Neurosonic headquartered?
- Neurosonic is headquartered in London, GB.